Release Pattern of the Vascular Plasminogen Activator and Its Inbibitor in Human Postvenous Occlusion Plasma as Assessed by a Spectrophotometric Solid-Phase Fibrin-tPA Activity Assay

E Anglés-Cano; B Boutière; D Arnoux; C Masson; G Contant; P Benchimol; J Sampol

doi:10.1055/s-0038-1646002

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1987; 58(03): 843-849
DOI: 10.1055/s-0038-1646002

Original Article

Schattauer GmbH Stuttgart

Release Pattern of the Vascular Plasminogen Activator and Its Inbibitor in Human Postvenous Occlusion Plasma as Assessed by a Spectrophotometric Solid-Phase Fibrin-tPA Activity Assay^[1]

E Anglés-Cano

^*INSERM U. l43, Institut de Pathologie Cellulaire, Hôpital de Bicêtre, Paris

,

B Boutière

The Laboratoire d’hématologie, Hôpital de la Conception, Marseille, France

,

D Arnoux

The Laboratoire d’hématologie, Hôpital de la Conception, Marseille, France

,

C Masson

^*INSERM U. l43, Institut de Pathologie Cellulaire, Hôpital de Bicêtre, Paris

,

G Contant

^**The Laboratoire Serbio, Asnières, Marseille, France

,

P Benchimol

The Laboratoire d’hématologie, Hôpital de la Conception, Marseille, France

,

J Sampol

The Laboratoire d’hématologie, Hôpital de la Conception, Marseille, France

› Institutsangaben

Abstract

als PDF herunterladen

Summary

Vascular or tissue-type plasminogen activatbr(plasma t-PA) is the circulating physiological fibrinolytic enzyme of endothelial cell origin which function is regulated by fibrin and a specific inhibitor (PAI). To study the pattern of release of t-PA and the behavior of t-PA-PAI complexes in plasma. we determined t-PA activity in 44 healthy subjects before and after 10 min offorearm venous occlusion using a new spectrophotmnetrio solid-phase fibrin-tPA activity assay. The assay is based on 1) the high affinity binding of t-PA tofibrin, and 2) the detection of fibrin-bound t-PA by measuring the release of pNA from a chromogenic substrate in the presence of plasminogeu. Values at.rest were rather undetectable in plasma (0.05 ± 0.03 IU/ml, in 23 out of 44 samples) but were positively detected in all the euglobulins: 0.88 ± 0.68 IU/ml. After venous occlusion the majority ofplasmas (36 out of 44) shoWed a slight increase in t-PA activity (0.65 ± 0.63 IU/ml) as compared to the important level observed in all the euglobulins (9.78 ± 9.58 IU/ml). So, the ratio plasma/euglobulin t-PA activity was very low (0.06) and remained identical in both pre- and postocclusion samples. However, when diluted plasmas were tested the inhibitory effect disappeared and t-PA activity increased indicating that although t-PA circulates in a neutralized state it can be available for fibrinolysis. Since 1) no binding of α₂ antiplasmin to fibrin in solid-phase could be demonstrated, 2) there was no correlation between α₂ antiplasmin and t-PA activity, and 3) a PAI-depleted plasma with a normal content of α₂ antiplasmin did not suppress the activity of t-PA, the inhibitory effect was attributed to PAL Our findings suggest that both t-PA and PAI are released. by venous occlusion and circulates in plasma as a t-PA-PAI complex.

Keywords

t-PA activity - PA inhibitor - Venous occlusion - Solid-phase fibrin - Spectrophotometric assay

PDF (259 kb)

Referenzen

References
1 Todd AS. The histological localization of fibrinolysin activator. J Pathol Bacteriol 1959; 78: 281-283
2 Camiolo SM, Thorsen S, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 1971; 38: 277-281
3 Thorsen S, Glas-Greenwalt P, Astrup T. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diathes Haemorrh 1972; 28: 65-74
4 Astrup T. Fibrinolysis in the organism. Blood 1956; 11: 781-806
5 Binder BR, Spragg J, Austen KF. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 1979; 254: 1998-2003
6 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
7 Angles-Cano E, Balaton A, Le Bonniec B, Genot E, Elion J, Sultan Y. Production of monoclonal antibodies to the high fibrin affinity tissue-plasminogen activator of human plasma. Demonstration of its endothelial origin by immunolocalization. Blood 1985; 66: 913-920
8 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3282
9 Niewiarowski S, Prou-Waftelle O. Role du facteur contact (facteur Hageman) dans la fibrinolyse. Thromb Diath Haemorrh 1959; 3: 593-603
10 Biggs R, Macfarlane RG, Pilling J. Observations on fibrinolysis. Experimental production by exercise or adrenaline. Lancet 1947; I: 402-404
11 Clarke RL, Urandi A, Chilton LL. Induction of fibrinolysis by venous obstruction. Angiology 1960; 11: 367-370
12 Ilolemans R. Increase in fibiiuulytie activity by venous occlusion. J Applied Physiol 1963; 18: 1123-1129
13 Cash JD. Short-term enhancement of plasminogen activator in vivo by drugs. Thromb Diath Haemorrh 1975; 34: 648-651
14 Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. J Biol Chem 1984; 259: 3644-3647
15 Wiman B, Mellbring G, Ranby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279-288
16 Verheijen JH, Mullaart E, Chang G TG, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1983; 48: 266-269
17 Allen RA. An enhancing effect of poly-lysine on the activation of plasminogen. Thromb Haemostas 1982; 47: 41-45
18 Angles-Cano E. A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high fibrin affinity tissue plasminogen activators. Anal Biochem 1986; 153: 201-210
19 Boutiere B, Arnoux D, Benchimol P, Sampol J, Angles-Cano E. Solid-phase fibrin-tissue-plasminogen-activator activity assay (SOFIA-tPA): tPA but not UK is specifically detected. Thromb Res 1986; 43: 129-132
20 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
21 Teger-Nilsson AC, Friberger P, Gysander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Clin Lab Invest 1977; 37: 403-409
22 Kazal LA, Amsel S, Miller OP, Tocantis LM. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963; 113: 989-994
23 Engvall E, Ruoslahti E. Binding of soluble forms of fibroblast surface protein, fibronectin, to collagen. Int J Cancer 1977; 20: 1-5
24 Blomback B, Blomback M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-443
25 Wallen P, Wiman B. Characterization of human plasminogen. 11. Separation and partial characterization of different molecular forms of human plasminogen. Biochim Biophys Acta 1972; 257: 122-134
26 Gaffney PJ, Curtis AD. A collaborative study of a proposed International Standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
27 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
28 Angles-Cano E, Sultan Y. A solid-phase fibrin immunoassay for the specific detection of monoclonal antibodies against different epitopic determinants of tissue plasminogen activators. J Immunol Meth 1984; 69: 115-127
29 Carrell R, Travis J. α₁-antitrypsin and the serpins: variation and countervariation. TIBS 1985; 10: 20-24
30 Angles-Cano E, Rondeau E, Delarue F, Hagege J, Sultan Y, Sraer JD. Identification and cellular localization of plasminogen activators from human glomeruli. Thromb Haemostas 1985; 54: 688-692
31 Angles-Cano E, Pannell R, Gurewich V. Pro-urokinase, the singlechain urokinase-type plasminogen activator does not bind to fibrin. Blood 1986; 68 suppl. (01) 343a
32 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257: 2912-2919
33 Laidler KJ, Bunting PS. The kinetics of immobilized enzyme systems. Meth Enzymol 1980; 64: 227-248
34 Godstein L. Kinetic behavior of immobilized enzyme systems. Meth Enzymol 1980; 64: 397-443
35 Angles-Cano E, Le Bonniec B. Plasminogen (Pg) activation kinetics by crude or pure tissue-type Pg-activator (t-PA) using a spec- trophotometric solid-phase fibrin-tPA activity assay as determined by computer analysis. Thromb Haemost 1985; 54: 163 (abstr.)
36 Kosow DP. Kinetic mechanism of the activation of human plasminogen by streptokinase. Biochemistry 1975; 14: 4459-4464
37 Drapier JC, Tenu JP, Lemaire G, Petit JF. Regulation of plasminogen activator secretion in mouse peritoneal macrophages. Biochimie 1979; 61: 463-471
38 Petersen LCh, Brender J, Suenson E. Zymogen activation kinetics. Biochem J 1985; 225: 149-158
39 Angles-Cano E, Masson C, Boutiere B. The activation pathway of plasminogen by solid-phase fibrin-bound tissue plasminogen activator does not involve lys-plasminogen intermediates. Fibrinolysis 1987; 1 (suppl.) 77 (abstr.)
40 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
41 Korninger C, Wagner O, Binder BR. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50000 antiactivator. J Lab Clin Med 1985; 105: 718-724
42 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis; low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
43 Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzymatic-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-6808
44 Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99-110
45 Miillertz S. Mechanism of activation and effect of plasmin in blood. Acta Physiol Scand 1956; 38 Suppl. (130) 1-66
46 Gurewich V, Hyde E, Lipinski B. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs. Blood 1975; 46: 555-565
47 Kluft C. Occurrence of Cl inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity. Haemostasis 1976; 5: 136-146
48 Verheijen JH, Chang G TG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
49 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator- inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 1984; 802: 111-118
50 Kruithof E KO, Tran-Thang Ch, Ransijn A, Bachman F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
51 Fearnley GR, Tweed JM. Evidence of an active fibrinolytic enzyme in the plasma of normal people with observations on inhibition associated with the presence of calcium. Clin Sci 1953; 12: 81-89
52 Fearnley GR, Lackner R. The fibrinolytic activity of normal blood. Br J Haematol 1955; 1: 189-198

Release Pattern of the Vascular Plasminogen Activator and Its Inbibitor in Human Postvenous Occlusion Plasma as Assessed by a Spectrophotometric Solid-Phase Fibrin-tPA Activity Assay[1]

Release Pattern of the Vascular Plasminogen Activator and Its Inbibitor in Human Postvenous Occlusion Plasma as Assessed by a Spectrophotometric Solid-Phase Fibrin-tPA Activity Assay^[1]